IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Fourteen percent of the world's people -- more than 800 million -- now have diabetes, a doubling of the global rate for the ...

The total number of adults living with either type 1 or type 2 diabetes in the world has surpassed 800 million—over four ...

People living with type 2 diabetes face several significant health challenges. The condition, which affects more than 10% of ...

People with chronic kidney disease, type 2 diabetes, or both of these conditions may have a higher cardiovascular disease ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The study, backed by the WHO, was released to mark World Diabetes Day on Thursday. It conducts a comparison between the ...

According to the study, in 2022, approximately 828 million adults aged 18 and older were living with either type 1 or type 2 ...

In 2022, there were around 828 million people aged 18 years and older with type 1 and type 2 diabetes worldwide, the study ...